Literature DB >> 21162653

Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy.

Denis F Frenzel1, Johannes M Weiss.   

Abstract

Osteopontin (OPN) is a phosphoglycoprotein that is expressed by various immune cells in a secreted and intracellular form. It has cytokine, chemotactic and cell signaling functions enhancing Th1 and Th17 immunity and protects against apoptosis. Recent studies found OPN to be modulatory in cell-mediated and immediate-type allergic diseases. In allergic asthma, OPN enhances sensitization but downmodulates Th2-driven IL-4-dominated inflammation. The finding that OPN expression is augmented during specific immunotherapy supports a Th2 suppressive effect of OPN. In Th1-driven delayed-type allergy, such as allergic contact dermatitis, OPN supports dendritic cell migration and IL-12 expression and is secreted by T effector cells and keratinocytes, augmenting Th1-mediated allergy and supporting disease chronification. There are numerous missing links as to how OPN variants modulate allergic inflammation through different OPN receptors. OPN research in allergy is an interesting, rapidly expanding field that has high potential for translational research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21162653     DOI: 10.1586/eci.10.82

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  11 in total

1.  Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis.

Authors:  Hye-In Ji; Sang-Hoon Lee; Ran Song; Hyung-In Yang; Yeon-Ah Lee; Seung-Jae Hong; Somi Kim; Yong-Beom Park; Soo-Kon Lee; Myung Chul Yoo; Kyoung Soo Kim
Journal:  Clin Rheumatol       Date:  2013-09-01       Impact factor: 2.980

2.  C-terminal modification of osteopontin inhibits interaction with the αVβ3-integrin.

Authors:  Brian Christensen; Eva Kläning; Mette S Nielsen; Mikkel H Andersen; Esben S Sørensen
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

Review 3.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

4.  Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic airway secretions.

Authors:  Mehrdad Arjomandi; Jessica Frelinger; Aneesh Donde; Hofer Wong; Amritha Yellamilli; Wilfred Raymond
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

5.  Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling.

Authors:  Yanlan Chai; Juan Wang; Ying Gao; Tao Wang; Fan Shi; Jin Su; Yunyi Yang; Xi Zhou; Liping Song; Zi Liu
Journal:  J Radiat Res       Date:  2014-09-24       Impact factor: 2.724

6.  Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Downregulates Osteopontin in Human Peripheral Blood Mononuclear Cells.

Authors:  Beata Kaleta; Agnieszka Boguska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-02-16       Impact factor: 4.291

7.  Immobilized Osteopontin Enhances Adhesion but Suppresses Cytokine Release of Anti-IgE Activated Human Mast Cells.

Authors:  Chun Wai Ng; Issan Yee San Tam; Sze Wing Sam; Yangyang Yu; Hang Yung Alaster Lau
Journal:  Front Immunol       Date:  2018-05-22       Impact factor: 7.561

Review 8.  Role of osteopontin in systemic lupus erythematosus.

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-06-11       Impact factor: 4.291

9.  Correlation between Serum Osteopontin and miR-181a Levels in Allergic Rhinitis Children.

Authors:  Wenlong Liu; Qingxiang Zeng; Renzhong Luo
Journal:  Mediators Inflamm       Date:  2016-04-21       Impact factor: 4.711

10.  The preliminary association study of osteopontin 707 C/T polymorphism with systemic lupus erythematosus in a Polish population.

Authors:  Beata Kaleta; Piotr Mróz; Andrzej Górski; Jacek Łukaszkiewicz; Anna Woźniacka; Jarosław Bogaczewicz
Journal:  Postepy Dermatol Alergol       Date:  2020-05-05       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.